Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C results in $46mm for Cempra Pharmaceuticals

Executive Summary

Antibiotics developer Cempra Pharmaceuticals closed a $46mm Series C financing round led by Quaker BioVentures, which adds a board member. Other first-time backer Devon Park Bioventures was joined by returning shareholders Aisling Capital, Intersouth Partners, Teachers' Private Capital, and investment banker Wistar Morris III. The money will support ongoing clinical development of CEM101 for community-acquired bacterial pneumonia and CEM102 for gram-positive infections, and to continue preclinical studies on its non-antibacterial macrolide candidates. Cempra had brought in $10mm in a Series B financing; investors that time were Aisling, Intersouth, Mr. Morris, plus the Ontario Teachers' Pension Plan as a new participant.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies